SCHEMBL3586855

SCHEMBL3586855

Cc1ccc(-c2ccc3cnn(CC(=O)NCCNCC4CCCCC4)c3c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.44
CNR1 P21554 1/20 0.43
RAB9A P51151 3/20 0.42
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MITF O75030 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
RECQL P46063 1/20 0.42
MDM2 Q00987 1/20 0.42
TSHR P16473 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPC1 O15118 2/20 0.41
KDM4E B2RXH2 6/20 0.40
HSD17B10 Q99714 5/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C19 P33261 1/20 0.40
MAPK1 P28482 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603706 0.84 KMO (0.46) BRD4RAB9AALDH1A1SMN1; SMN2MITF
SCHEMBL3586854 0.83 KDM4E (0.42) BRD4RAB9AALDH1A1SMN1; SMN2TSHR
SCHEMBL3602467 0.83 KDM4E (0.46) CNR1RAB9AALDH1A1SMN1; SMN2LMNA
SCHEMBL3602594 0.82 TSHR (0.57) RAB9AALDH1A1SMN1; SMN2MITFLMNA
SCHEMBL3591928 0.82 GRIN2B (0.46) CNR1RAB9AALDH1A1SMN1; SMN2LMNA
SCHEMBL3609348 0.80 NPC1 (0.40) CNR1RAB9AALDH1A1LMNATSHR
SCHEMBL3596908 0.80 POLB (0.40) CNR1RAB9AALDH1A1LMNAMAPT
SCHEMBL3605305 0.79 THRB (0.48) CNR1RAB9AALDH1A1SMN1; SMN2LMNA
SCHEMBL3603674 0.79 MTNR1A (0.41) CNR1RAB9ASMN1; SMN2TSHRL3MBTL1
SCHEMBL3596258 0.79 NPC1 (0.47) CNR1RAB9AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 BRD4 3682/4885CNR1 777/4885RAB9A 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.